Form 4: TScan Therapeutics Director Garry Nicholson Granted 67,000 Stock Options

TScan Therapeutics, Inc. Director Garry A. Nicholson was granted 67,000 stock options with an exercise price of $1.45, vesting by June 30, 2026, or the next annual meeting.

Summary

• Garry A. Nicholson, a Director of TScan Therapeutics, Inc. (TCRX), was granted 67,000 stock options.
• The options have an exercise price of $1.45 per share.
• The options will vest in full upon the earlier of June 30, 2026, or the next annual meeting of the Issuer's stockholders, contingent on continued service.
• The options expire on June 30, 2035.
• The transaction date for the grant was June 30, 2025.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal of alignment between management and shareholder interests, and a standard practice for incentivizing long-term performance. It's a routine compensation event, not indicative of major positive or negative operational news, hence a neutral-to-slightly positive score.

Positives

• Granting stock options to a director aligns their interests with shareholders, incentivizing long-term performance and stock price appreciation.
• The exercise price of $1.45 provides a clear target for value creation.

Negatives

• The grant of options could lead to dilution if exercised, though this is a standard compensation practice.

Risks

• No specific risks are detailed in this Form 4 filing beyond the inherent risks of stock-based compensation, such as potential future dilution upon exercise.

Future Outlook

The vesting schedule of the stock options, tied to continued service and future dates (June 30, 2026, or the next annual meeting), indicates an expectation of the director's ongoing contribution to the company's performance.

Management Comments

• No direct quotes or paraphrased statements from management are included in this Form 4 filing, which primarily reports a transaction.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, including companies like TScan Therapeutics, Inc., to attract and retain executive talent and align their incentives with long-term shareholder value creation. This type of compensation is standard across publicly traded companies, particularly in growth-oriented sectors where future potential is a key driver of value.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across publicly traded companies, especially in the biotech sector.
• While specific comparable companies or projects are not mentioned, the structure of the option grant (exercise price, vesting schedule, and expiration) is typical for director compensation packages aimed at incentivizing long-term commitment and performance.
• The exercise price of $1.45 would be evaluated against the company's stock price at the time of grant to determine if it was 'at-the-money' or 'out-of-the-money', which is a common practice.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings are mentioned in this Form 4 filing.

Related Party Transactions

• The stock option grant to a director is a related party transaction, as directors are considered related parties. This is a standard compensation arrangement.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to increased efforts to enhance share value. However, future exercise of options could result in minor dilution.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The stock options will vest upon the earlier of June 30, 2026, or the next annual meeting of the Issuer's stockholders, subject to continued service.

Key Dates

Recommendation

Keywords

TScan Therapeutics, TCRX, Stock Option, Form 4, Director Compensation, Equity Grant, Beneficial Ownership, Garry A. Nicholson